Zydus Cadila Joins IO Therapy League With XOMA Tie-up

IL-2 Therapy Use So Far Limited By Toxicities

Cadila Healthcare has entered the immuno-oncology race by inking a licensing agreement with US-based XOMA for a drug candidate that combines the Indian firm's interleukin-2 with the latter’s novel anti-IL-2 monoclonal antibody

Perfect business partnership as a connecting puzzle shaped as two trees in the form of human heads connecting together as a corporate success metaphor for cooperation and agreement as equal partners.
Cadila And XOMA Hope Their Combination Will Be A Win-Win • Source: Shutterstock

Cadila Healthcare Ltd., the flagship firm of India's Zydus Cadila group, has entered the league of companies researching interleukin (IL) therapies through a tie-up with Emeryville, California-based Xoma Corp. for an immuno-oncology (IO) drug candidate that combines Zydus’s IL-2 product with XOMA’s novel anti-IL-2 monoclonal antibody.

Cadila will conduct clinical trials for the IL-2 therapy and have exclusive rights to develop and commercialize this in India,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip